

AMENDMENTS TO THE ABSTRACT:

Please amend the Abstract originally appearing on page 25 of the application as follows:

ABSTRACT OF THE DISCLOSURE

A method is provided in which ~~2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.0<sup>5,9</sup>0<sup>3,11</sup>]-dodecane~~ ~~2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.0<sup>5,9</sup>0<sup>3,11</sup>]-dodecane~~ (CL-20 or HNIW) is crystallized to its  $\epsilon$ -polymorph by an inverse precipitation technique. A dry CL-20 solvent solution containing an amount of CL-20 dissolved in a CL-20 solvent is prepared. The dry solvent solution is added to a crystallizer containing a ~~CL-20~~ ~~CL-20~~ non-solvent to cause precipitation of epsilon polymorph CL-20 crystals by the inverse precipitation technique. The precipitated epsilon polymorph CL-20 crystals are separated from the non-solvent and the solvent.